Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Report Date: October 30, 2025
Reporting Period: Quarter ended September 30, 2025
Context: The filing announces financial results for the quarter and provides a business update. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document and does not contain specific numerical data. The filing states that the full financial results are located in the attached press release (Exhibit 99.1). Consequently, the following metrics are not available in the source text:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide specific data to compare against the prior comparable period. Material changes in financial condition or operations are detailed in the referenced Exhibit 99.1 press release, which is not included in the input text.
Guidance, Outlook, and Risks
Management Commentary: The company announced a business update alongside the financial results, but the specific content of this update is not present in the 8-K text.
Guidance and Outlook: No forward-looking guidance or outlook figures are provided in the filing text.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash burn figures for the quarter ended September 30, 2025.
- Verify the specific details of the "business update" mentioned in the filing, as these are not summarized in the 8-K text.
- Check for any updated clinical trial milestones or regulatory developments referenced in the press release.
- Confirm the company's current cash runway and liquidity status from the detailed financial statements in the press release.